The Treat-to-Target Project in Atopic Dermatitis: One Year On


  • Marjolein de Bruin-Weller Department of Allergology and Dermatology, UMC Utrecht, National Expertise Center for Eczema, Utrecht, The Netherlands
  • Mette Deleuran Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark
  • Tilo Biedermann Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany
  • Robert Bissonnette Innovaderm Research, Montreal, QC, Canada
  • Peter Foley The University of Melbourne, St Vincent’s Hospital Melbourne, Melbourne, Australia; Probity Medical Research, Skin Health Institute, Melbourne, Victoria, Australia
  • Giampiero Girolomoni Department of Medicine, Section of Dermatology and Venereology, University of Verona, Italy
  • Jana Hercogová Institute of Clinical and Experimental Medicine, Prague, Czech Republic
  • Chih-Ho Hong Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada
  • Norito Katoh Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto, Japan
  • Andrew Pink St John’s Institute of Dermatology, Guy’s and St, Thomas’ NHS Foundation Trust, London, UK; Department of Dermatology, Kings College, London, UK
  • Marie-Aleth Richard CEReSSEA 3279, Research Center in Health Services and Quality of Life, Aix Marseille University, Marseille, France; Department of Dermatology, University Hospital of La Timone, Marseille, France; Dermatology Department, Assistance Publique Hôpitaux de Marseille, APHM, Marseille, France
  • Stephen Shumack Department of Dermatology, Royal North Shore Hospital, Sydney, New South Wales, Australia
  • Juan Francisco Silvestre Department of Dermatology, Hospital General de Alicante, Alicante, Spain
  • Jacob P. Thyssen Department of Dermatology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark
  • Stephan Weidinger Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany



atopic dermatitis, consensus, systemic treatment, treat-to-target


Atopic dermatitis is a chronic skin condition for which a range of systemic treatments have recently been approved. A treat-to-target strategy has been developed previously alongside an algorithm to guide the management of patients with atopic dermatitis. Here, we review the strategy and algorithm in the context of the evolving therapeutic landscape, and identify areas for further refinement and development.


Download data is not yet available.


Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657-682. DOI:

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850-878. DOI:

De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol 2021; 101: adv00402. DOI:

Larsen HH, Vittrup I, Ruge IF, Elberling J, Skov L, Ibler K, et al. Severe and ChRonic Atopic dermatitis Treatment CoHort (SCRATCH): a Danish real-world evidence atopic dermatitis treatment registry. Acta Derm Venereol 2022; 102: adv00760. DOI:

Bagel J, Nguyen TQ, Lima H, Jain N, Pariser DM, Hsu S, et al. Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE). Dermatol Ther (Heidelb) 2022; 12: 1417-1430. DOI:

Siegels D, Haufe E, Heinrich L, Werfel T, Weidinger S, Schmitt J; TREATgermany Study Group. Status report on the atopic dermatitis registry TREATgermany. Allergol Select 2021; 5: 274-286. DOI:

Ariëns LFM, van der Schaft J, Spekhorst LS, Bakker DS, Romeijn GLE, Kouwenhoven TA, et al. Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-week results from the Dutch BioDay registry. J Am Acad Dermatol 2021; 84: 1000-1009. DOI:

Abuabara K, Silverberg JI, Simpson EL, Paller AS, Eichenfield LF, Bissonnette R, et al. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open 2020; 10: e039928. DOI:

Thyssen JP, Vestergaard C, Deleuran M, de Bruin-Weller MS, Bieber T, Taieb A, et al. European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. J Eur Acad Dermatol Venereol 2020; 34: e839-e842. DOI:



How to Cite

de Bruin-Weller, M., Deleuran, M., Biedermann, T., Bissonnette, R., Foley, P., Girolomoni, G., Hercogová, J., Hong, C.-H., Katoh, N., Pink, A., Richard, M.-A., Shumack, S., Silvestre, J. F., Thyssen, J. P., & Weidinger, S. (2023). The Treat-to-Target Project in Atopic Dermatitis: One Year On. Acta Dermato-Venereologica, 103, adv5382.





Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >>